MOLN · NASDAQ

Molecular Partners AG

Q: How do I get MOLN news from the API?

Call GET /v1/news?tickers=MOLN. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.

$3.25 +0.16 (+5.08%)

Company overview

Molecular Partners AG operates as a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic proteins. Its product candidates include Abicipar, a DARPin therapeutic candidate in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration and diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company also develops MP0310 in Phase Ia clinical trials for immuno-oncology, MP0317 in Phase I clinical trials as a tumor-localized immune agonist, and MP0274 in Phase I clinical trials for HER2-positive cancers.

Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
Market cap: $124M
Employees: 158
Headquarters: Schlieren
Website: molecularpartners.com
CEO: Patrick Amstutz
Listed: June 16, 2021
P/E: -2.08
Dividend yield: 0.00%

Company financials

Revenue: $0.00
Gross profit: -$2.6M
Operating income: -$65.7M
EBITDA: -$63.1M
Net income: -$72.1M
EPS: -$1.56
Total assets: $87.4M
Total debt: $3.3M
Earnings yield: -48.00%

Revenue segmentation

By product (FY 2024)

No product segmentation.

By region (FY 2024)

Showing FY 2024

Price chart

MOLN 1D NASDAQ O3.18H3.27L3.18C3.25+0.16 (+5.08%)Vol1.77K

News

Ticker	Type	Headline	Source	Published
MOLNMolecular Partners AG	Press release	Molecular Partners to Present on DLL3-Targeting Radio-DARPin MP0712 at 2026 SNMMI Theranostics Conference and NACLC 2026	GlobeNewswire	Nov 5, 1:00:01 AM ET
MOLNMolecular Partners AG	Stock news	After Plunging 18.3% in 4 Weeks, Here's Why the Trend Might Reverse for Molecular Partners AG Sponsored ADR (MOLN)	Zacks Investment Research	Nov 4, 8:35:02 AM ET
MOLNMolecular Partners AG	Press release	Molecular Partners Reports Q3 2026 Financial Results, Deepens Focus on Targeted Radiotherapy	GlobeNewswire	Oct 29, 2:00:00 AM ET
MOLNMolecular Partners AG	Press release	Molecular Partners Nominates MP0730 as Next Candidate in Expanding Pipeline of Radiotherapeutics, Targeting CD70	GlobeNewswire	Oct 22, 1:00:00 AM ET
MOLNMolecular Partners AG	Press release	Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study	GlobeNewswire	Aug 25, 1:00:00 AM ET
MOLNMolecular Partners AG	Press release	Molecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317	GlobeNewswire	May 12, 4:00:00 PM ET
MOLNMolecular Partners AG	Press release	Molecular Partners to hold oral presentations on DLL3-targeting Radio-DARPin candidate MP0712 at multiple upcoming scientific conferences	GlobeNewswire	May 4, 1:00:00 AM ET
MOLNMolecular Partners AG	Press release	Molecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodeling	GlobeNewswire	May 1, 7:00:00 AM ET
MOLNMolecular Partners AG	Stock news	Molecular Partners presents three posters at AACR 2026, with new preclinical data for first Switch-DARPin T cell engager MP0632 and DLL3 Radio-DARPin MP0712	GlobeNewswire	Apr 19, 12:00:00 PM ET
MOLNMolecular Partners AG	Press release	Molecular Partners presents three posters at AACR 2026, with new preclinical data for first Switch-DARPin T cell engager MP0632 and DLL3 Radio-DARPin MP0712	GlobeNewswire	Apr 19, 12:00:00 PM ET
MOLNMolecular Partners AG	Press release	Molecular Partners Announces all Board Proposals Approved, Clare Fisher Elected as New Board Member at Annual General Meeting	GlobeNewswire	Apr 14, 4:00:00 PM ET
MOLNMolecular Partners AG	Press release	Molecular Partners Publishes Invitation to Annual General Meeting 2026 and Proposes Clare Fisher for Election to its Board of Directors	GlobeNewswire	Mar 23, 9:00:00 AM ET
MOLNMolecular Partners AG	Press release	Molecular Partners Presents New Preclinical Data Highlighting Radio-DARPins' Amenability to Multiple Isotopes	GlobeNewswire	Mar 19, 2:00:00 AM ET
MOLNMolecular Partners AG	Press release	Molecular Partners to Hold Three Poster Presentations at AACR 2026	GlobeNewswire	Mar 17, 4:30:00 PM ET
MOLNMolecular Partners AG	Press release	Molecular Partners Reports Highlights and Financial Results for Full Year 2025	GlobeNewswire	Mar 12, 4:00:00 PM ET
MOLNMolecular Partners AG	Press release	Molecular Partners Announces Participation in March Investor Conferences and Upcoming 2025 Financial Results	GlobeNewswire	Feb 26, 1:00:00 AM ET
MOLNMolecular Partners AG	Stock news	Molecular Partners AG (MOLN) Discusses Clinical Imaging and Dosimetry Data for DLL3 Targeting Radiotherapeutic MPO712 Transcript	Seeking Alpha	Feb 2, 4:10:28 PM ET
MOLNMolecular Partners AG	Press release	Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026	GlobeNewswire	Feb 2, 1:00:00 AM ET
MOLNMolecular Partners AG	Stock news	Molecular Partners AG (MOLN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript	Seeking Alpha	Jan 15, 5:16:01 PM ET
MOLNMolecular Partners AG	Stock news	Molecular Partners Highlights Clinical Development Progress and Anticipated Milestones at 44th Annual J.P. Morgan Healthcare Conference	GlobeNewswire	Jan 11, 3:00:00 PM ET

FAQ

Questions about Molecular Partners AG

What does Molecular Partners AG do?

What is MOLN's market cap?

Molecular Partners AG (MOLN) is a listed stock with a live quote. The latest market cap on this page is $124M.

Where is Molecular Partners AG headquartered?

Molecular Partners AG is headquartered in Schlieren.

How do I get MOLN news from the API?

Call GET /v1/news?tickers=MOLN. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.

How far back does MOLN news go?

Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for MOLN, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.

Is the MOLN price on this page from the API?

The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.

Can I use the Pro plan commercially?

No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs